Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study - PubMed
3 hours ago
- #IgA nephropathy
- #telitacicept
- #immunosuppressive therapy
- Study compares telitacicept monotherapy vs. telitacicept + glucocorticoid/mycophenolate mofetil (GM) for IgA nephropathy (IgAN).
- 256 patients enrolled: 125 on telitacicept alone, 131 on telitacicept + GM.
- Telitacicept + GM showed greater reduction in proteinuria (-1.32 g/day vs. -0.94 g/day, P < 0.001).
- Better eGFR slope in telitacicept + GM group (2.74 mL/min/1.73 m²/year vs. -0.56 mL/min/1.73 m²/year, P = 0.014).
- Higher remission rates in telitacicept + GM group (complete: 54.2% vs. 40.8%; overall: 78.6% vs. 70.4%).
- Multivariable analysis confirmed higher likelihood of remission with telitacicept + GM (adjusted HR 2.18 for complete remission).
- Telitacicept + GM had higher adverse event incidence (28.2% vs. 11.2%), but no serious adverse events reported.
- Conclusion: Telitacicept + GM is effective in reducing proteinuria/hematuria and preserving renal function in IgAN.